German firm MagForce and its MagForce USA division have obtained investigational device exemption (IDE) approval from the US Food and Drug Administration (FDA) to study NanoTherm therapy as a focal ablation treatment in a clinical trial for intermediate risk prostate cancer.

The IDE approval allows the firm to perform a clinical trial at select medical centres in the country.

Developed for the local treatment of solid tumours, NanoTherm therapy is based on the direct introduction of magnetic nanoparticles into a tumour and subsequent heating in an alternating magnetic field.

According to MagForce, the treatment duration and temperatures achieved within the tumour result in irreparable damage or sensitisation of the cancer cells for further chemo or radiotherapy.

“The focal ablation of cancer lesions is expected to enable maintenance of such patients in active surveillance programmes, eliminating the need for definitive therapies.”

The firm also claims that the approach spares surrounding healthy tissue, as well as facilitates repeated treatments and multimodal therapy concepts as the nanoparticles remain at the treatment site.

Expected to start enrolment over the next few months, the focal thermal ablation registration single-arm IDE trial will include approximately 120 subjects.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The primary objective of the trial is to validate the capability of NanoTherm to focally ablate cancer lesions in patients who are suffering from advanced to intermediate risk prostate cancer stage and are under active surveillance.

The focal ablation of cancer lesions is expected to enable maintenance of such patients in active surveillance programmes, eliminating the need for definitive therapies such as surgery or whole gland radiation that are known to have side effects.